Well, I'll tell you what, the one I -- I'm going to ease my way out of this one a little bit, but one thing is just looking historically, sometimes it's good to just point to people that it's historically happened, so you can say it publicly out there. We have been having a couple of million dollars with the DiePaks in Q4, I think, each of the last three, four years or so, right? And normally, what we get is we get a set of DiePaks somewhere around fall and then that turns into production around May. I've, kind of, made it pretty specific back as we would have expected again this time, but then you got pushed into the summer, so that's one example. So that type of device has generally been maybe a few million dollars a year of just the consumables. This new application, I am going to just simply say there will be more and a test cell is $4.3 million or $4 million or so. So they come in pretty good-sized chunks. We have ranges of what it is and we also know that all of the deep data is not in. And our visibility of this is actually still relatively limited. Meaning, we can see the capacity needs maybe over the next six or nine months or so, but we will see as the device finally gets out in its deployment, in all the different devices, what the growth rate is. I'll tell you, I'll share one thing, and I can -- I think this is okay to say. I have been told by the customers, you could think of even this one in the past, this is how big it is and how great it's going to be, and then they have not bought that much. And this is a customer that has certainly done that before. This time, they told us less about how great it's going to be, but it's more obvious from their actions how big it's going to be. So I don't know if that's a good thing, but it seems like when they tell us how great it is, it isn't as big as it is. And maybe the fact that they haven't said as much this time, maybe that's a good sign or not, but we know it's going to -- it's a good-sized deal and building more revenue and bookings.